Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2016 07:30 ET | Source: Aceragen, Inc.

Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor at AACR Annual Meeting 2016

CAMBRIDGE, Mass. and EXTON, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
April 11, 2016 10:30 ET | Source: Aceragen, Inc.

Idera to Present at the 15th Annual Needham Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., April 11, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
March 10, 2016 07:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., March 10, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
March 03, 2016 11:30 ET | Source: Aceragen, Inc.

Idera to Present at Two March Investor Healthcare Conferences

CAMBRIDGE, Mass. and EXTON, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
January 06, 2016 08:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Appointment of Dr. Maxine Gowen to Its Board of Directors

CAMBRIDGE, Mass. and EXTON, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
January 05, 2016 08:00 ET | Source: Aceragen, Inc.

Idera to Present at the 34th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
December 14, 2015 08:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Trial of Intra-tumoral IMO-2125 in Combination With Ipilimumab in Patients With Metastatic Melanoma

CAMBRIDGE, Mass. and EXTON, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
December 05, 2015 17:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia

ORLANDO, Fla., Dec. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for...
November 30, 2015 08:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Several Key Leadership Additions

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
November 23, 2015 08:00 ET | Source: Aceragen, Inc.

Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...